+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Cell Therapy Market Size, Share & Trends Analysis Report by Therapy Type (Autologous (Stem Cell Therapies, Non-stem Cell Therapies), Allogeneic), Therapeutic Area, Region, and Segment Forecasts, 2024-2030

  • PDF Icon

    Report

  • 110 Pages
  • January 2024
  • Region: Global
  • Grand View Research
  • ID: 4700911
The global cell therapy market is expected to reach USD 20.07 billion by 2030, expanding at a CAGR of 22.66% from 2024 to 2030. The market players are witnessing an increasing interest in the development of advanced therapies that are based on tissue, genes, or cells. Research communities and companies continue to make large investments in the culturing and isolation of a broad range of cell types, such as keratinocytes, chondrocytes, cartilage, stem, dermal papilla, & epithelial cells for the development of novel therapies.

Regulatory authorities such as FDA play a crucial role in the growth of the market by undertaking initiatives related to the development and approval of advanced treatment development as well as restriction of unregulated treatments. In addition, direct cellular reprogramming is attracting interest as a cutting-edge treatment approach because of its advantages such as efficacy and security.

On the other hand, an increase in the number of clinical trials related to advanced therapies is expected to boost the market growth in the coming years. According to data obtained from the American Society of Gene & Cell Therapy, in Q1 2022, 32 non-genetically modified cellular therapeutics trials were initiated, and 69% of these were in the non-oncology arena. Moreover, according to ClinicalTrials.gov, more than 1800 active cellular therapies are under clinical trial.

Furthermore, key companies operating in the market are undertaking several strategic initiatives such as various agreements, new launches, and expansion to strengthen their market presence. For instance, in May 2022, the University of Pennsylvania's personalized cellular therapy was approved for the treatment of individuals with relapsed or resistant follicular lymphoma.

Moreover, in April 2021, Bristol Myers Squibb declared that U.S. FDA approved its Breyanzi (lisocabtagene maraleucel), a novel CAR T treatment for adults with R/R large B-cell lymphoma. In the pivotal trial for 3L+ LBCL, TRANSCEND NHL 001, Breyanzi showed a 73% overall response rate and a 54% complete response (CR) rate.

Cell Therapy Market Report Highlights

  • The autologous therapy segment dominated the market with the largest revenue share of 91.22% in 2023, owing to increasing adoption of this therapy type coupled with lower risk of life-threatening complications
  • The allogenic therapy segment is expected to grow significantly in the coming years owing to factors such as high pricing and growth in stem cell banking. Moreover, many companies are preparing to shift their business toward allogenic cell therapy product development
  • Oncology therapeutic area captured the largest market share in 2023, owing to the increasing adoption of advanced cell therapies in the treatment of various types of cancers
  • Cell therapy are also under the investigation for musculoskeletal disorders and has great potential for market growth
  • North America dominated the market owing to the strong regulatory framework, presence of bodies like the International Society for Cellular Therapy, and presence of key operating companies

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Therapy Type Segment
1.1.2. Therapeutic Area Segment
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased Database
1.3.2. Internal Database
1.3.3. Secondary Sources
1.3.4. Primary Research
1.4. Information or Data Analysis
1.4.1. Data Analysis Models
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List Of Secondary Sources
1.8. List Of Primary Sources
1.9. Objectives
1.9.1. Objective 1
1.9.2. Objective 2
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Landscape Insights
Chapter 3 Market Variables, Trends, & Scope
3.1 Market Lineage Outlook
3.1.1 Parent Market Outlook
3.1.2 Ancillary Market Outlook
3.2 Market Dynamics
3.2.1 Market Driver Analysis
3.2.1.1 Rise In The Number Of Clinical Studies Pertaining To The Development Of Cellular Therapies
3.2.1.2 Rising Adoption Of Regenerative Medicine
3.2.1.3 Introduction Of Novel Platforms And Technologies
3.2.2 Market Restraint Analysis
3.2.2.1 Ethical Concerns Related To Stem Cell Research
3.2.2.2 Clinical Issues Pertaining To Development & Implementation Of Cell Therapy
3.3 Industry Analysis Tools
3.3.1 Porter’s Five Forces Analysis
3.3.2 PESTEL Analysis
3.3.3 COVID-19 Impact Analysis
Chapter 4 Cell Therapy Market Categorization: Therapy Type Estimates & Trend Analysis
4.1 Allogeneic Cell Therapy
4.1.1 Global Allogeneic Cell Therapy Market, 2018-2030 (USD Billion)
4.1.2 Stem Cell Therapies
4.1.2.1 Global Allogeneic Cell Therapy Market For Stem Cell Therapies, 2018-2030 (USD Billion)
4.1.2.2 Hematopoeitic Stem Cell Therapies
4.1.2.2.1 Global Allogeneic Cell Therapy Market For Hematopoeitic Stem Cell Therapies, 2018-2030 (USD Billion)
4.1.2.3 Mesenchymal Stem Cell Therapies
4.1.2.3.1 Global Allogeneic Cell Therapy Market For Mesenchymal Stem Cell Therapies, 2018-2030 (USD Billion)
4.1.3 Non-Stem Cell Therapies
4.1.3.1 Global Allogeneic Cell Therapy Market For Non-Stem Cell Therapies, 2018-2030 (USD Billion)
4.1.3.2 Keratinocytes & Fibroblast-Based Therapies
4.1.3.2.1 Global Allogeneic Cell Therapy Market For Keratinocytes & Fibroblast-Based Therapies, 2018-2030 (USD Billion)
4.1.3.3 Others
4.1.3.3.1 Global Allogeneic Cell Therapy Market For Other Non-Stem Cell Therapies, 2018-2030 (USD Billion)
4.2 Autologous Cell Therapy
4.2.1 Global Autologous Cell Therapy Market, 2018-2030 (USD Billion)
4.2.2 Stem Cell Therapy
4.2.2.1 Global Autologous Cell Therapy Market For Stem Cell Therapy, 2018-2030 (USD Billion)
4.2.2.2 BM, Blood, & Umbilical Cord-Derived Stem Cells
4.1.2.2.1 Global Autologous Cell Therapy Market For BM, Blood, & Umbilical Cord-Derived Stem Cells, 2018-2030 (USD Billion)
4.2.2.3 Adipose Derived Cells
4.1.2.3.1 Global Autologous Cell Therapy Market For Adipose Derived Cells, 2018-2030 (USD Billion)
4.2.2.4 Others
4.2.2.4.1 Global Autologous Cell Therapy Market For Other Therapies, 2018-2030 (USD Billion)
4.2.3 Non-Stem Cell Therapy
4.2.3.1 Global Autologous Cell Therapy Market For Non-Stem Cell Therapy, 2018-2030 (USD Billion)
4.2.3.2 T-Cell Therapies
4.2.3.2.1 Global Autologous Cell Therapies Market For T-Cell Therapy, 2018-2030 (USD Billion)
4.2.4.2.2 CAR-T Cell Therapy
4.2.4.2.2.1 Global Autologous Cell Therapy Market For CAR-T Cell Therapy, 2018-2030 (USD Billion)
4.2.4.2.3 T-Cell Receptor (TCR)
4.2.4.2.3.1 Global Autologous Cell Therapy Market For T-Cell Receptor (TCR), 2018-2030 (USD Billion)
4.2.3.3 Others
4.2.3.3.1 Global Autologous Cell Therapies Market For Other Autologous Non-Stem Cell Therapies, 2018-2030 (USD Billion)
Chapter 5 Cell Therapy Market Categorization: Therapeutic Area Estimates & Trend Analysis
5.1 Cell Therapy Market: Therapeutic Area Movement Analysis
5.2 Oncology
5.2.1 Global Cell Therapy Market For Oncology Therapies, 2018-2030 (USD Million)
5.3 Cardiovascular Disease (CVD)
5.3.1 Global Cell Therapy Market For Cardiovascular Disease (CVD) Therapies, 2018-2030 (USD Million)
5.4 Musculoskeletal Disorders
5.4.1 Global Cell Therapy Market For Musculoskeletal Disorders Therapies, 2018-2030 (USD Million)
5.5 Dermatology
5.5.1 Global Cell Therapy Market For Dermatology Therapies, 2018-2030 (USD Million)
5.6 Others
5.6.1 Global Cell Therapy Market For Other Therapies, 2018-2030 (USD Million)
Chapter 6 Cell Therapy Market Categorization: Regional Estimates & Trend Analysis
6.1 North America
6.1.1 North America Cell Therapy Market Estimates And Forecasts, 2018-2030 (USD Million)
6.1.2 U.S.
6.1.2.1 Key Country Dynamics
6.1.2.2 Target Disease Prevalence
6.1.2.3 Competitive Scenario
6.1.2.4 Regulatory Framework
6.1.2.6 U.S. Cell Therapy Market Estimates And Forecasts, 2018-2030 (USD Million)
6.1.3 Canada
6.1.3.1 Key Country Dynamics
6.1.3.2 Target Disease Prevalence
6.1.3.3 Competitive Scenario
6.1.3.4 Regulatory Framework
6.1.3.6 Canada Cell Therapy Market Estimates And Forecasts, 2018-2030 (USD Million)
6.2 Europe
6.2.1 Europe Cell Therapy Market Estimates And Forecasts, 2018-2030 (USD Million)
6.2.2 Germany
6.2.2.1 Key Country Dynamics
6.2.2.2 Target Disease Prevalence
6.2.2.3 Competitive Scenario
6.2.2.4 Regulatory Framework
6.2.2.6 Germany Cell Therapy Market Estimates And Forecasts, 2018-2030 (USD Million)
6.2.3 UK
6.2.3.1 Key Country Dynamics
6.2.3.2 Target Disease Prevalence
6.2.3.3 Competitive Scenario
6.2.3.4 Regulatory Framework
6.2.3.6 UK Cell Therapy Market Estimates And Forecasts, 2018-2030 (USD Million)
6.2.4 Switzerland
6.2.4.1 Key Country Dynamics
6.2.4.2 Target Disease Prevalence
6.2.4.3 Competitive Scenario
6.2.4.4 Regulatory Framework
6.2.4.6 Switzerland Cell Therapy Market Estimates And Forecasts, 2018-2030 (USD Million)
6.3 Asia-Pacific
6.3.1 Asia-Pacific Cell Therapy Market Estimates And Forecasts, 2018-2030 (USD Million)
6.3.2 Japan
6.3.2.1 Target Disease Prevalence
6.3.2.2 Competitive Scenario
6.3.2.3 Regulatory Framework
6.3.2.5 Japan Cell Therapy Market Estimates And Forecasts, 2018-2030 (USD Million)
6.3.3 China
6.3.3.1 Target Disease Prevalence
6.3.3.2 Competitive Scenario
6.3.3.3 Regulatory Framework
6.3.3.5 China Cell Therapy Market Estimates And Forecasts, 2018-2030 (USD Million)
6.3.4 India
6.3.4.1 Target Disease Prevalence
6.3.4.2 Competitive Scenario
6.3.4.3 Regulatory Framework
6.3.4.5 India Cell Therapy Market Estimates And Forecasts, 2018-2030 (USD Million)
6.3.5 South Korea
6.3.5.1 Target Disease Prevalence
6.3.5.2 Competitive Scenario
6.3.5.3 Regulatory Framework
6.3.5.5 South Korea Cell Therapy Market Estimates And Forecasts, 2018-2030 (USD Million)
6.4 Rest Of The World
6.4.1 Rest Of The World Cell Therapy Market Estimates And Forecasts, 2018-2030 (USD Million)
Chapter 7 Competitive Landscape
7.1 Company Categorization
7.2 Strategy Mapping
7.3 Company Market Position Analysis, 2023
7.4 Company Profiles/Listing
7.4.1 Novartis AG
7.4.1.1 Company Overview
7.4.1.4 Financial Performance
7.4.1.3 Product Benchmarking
7.4.1.4 Strategic Initiatives
7.4.2 Gilead Sciences, Inc.
7.4.2.1 Company Overview
7.4.2.2 Financial Performance
7.4.2.3 Product Benchmarking
7.4.2.4 Strategic Initiatives
7.4.3 Bristol-Myers Squibb Company
7.4.3.1 Company Overview
7.4.3.2 Financial Performance
7.4.3.3 Product Benchmarking
7.4.3.4 Strategic Initiatives
7.4.4 Johnson & Johnson Services, Inc
7.4.4.1 Company Overview
7.4.4.2 Financial Performance
7.4.4.3 Product Benchmarking
7.4.4.4 Strategic Initiatives
7.4.5 JCR Pharmaceuticals Co., Ltd.
7.4.5.1 Company Overview
7.4.5.2 Financial Performance
7.4.5.3 Product Benchmarking
7.4.5.4 Strategic Initiatives
7.4.6 JW Therapeutics
7.4.6.1 Company Overview
7.4.6.2 Financial Performance
7.4.6.3 Product Benchmarking
7.4.6.4 Strategic Initiatives
7.4.7 Atara Biotherapeutics
7.4.7.1 Company Overview
7.4.7.2 Financial Performance
7.4.7.3 Product Benchmarking
7.4.7.4 Strategic Initiatives
7.4.8 MEDIPOST
7.4.8.1 Company Overview
7.4.8.2 Financial Performance
7.4.8.3 Product Benchmarking
7.4.8.4 Strategic Initiatives
7.4.9 Anterogen Co., Ltd.
7.4.9.1 Company Overview
7.4.9.2 Financial Performance
7.4.9.3 Product Benchmarking
7.4.9.4 Strategic Initiatives
7.4.10 S. BIOMEDICS
7.4.10.1 Company Overview
7.4.10.2 Financial Performance
7.4.10.3 Product Benchmarking
7.4.10.4 Strategic Initiatives
List of Tables
Table 1 List Of Secondary Sources
Table 2 Global Cell Therapy Market By Therapy Type, 2018-2030 (USD Million)
Table 3 Global Cell Therapy Market By Therapeutic Area, 2018-2030 (USD Million)
Table 4 Global Cell Therapy Market By Region, 2018-2030 (USD Million)
Table 5 North America Cell Therapy Market By Country, 2018-2030 (USD Million)
Table 6 North America Cell Therapy Market By Therapy Type, 2018-2030 (USD Million)
Table 7 North America Cell Therapy Market By Therapeutic Area, 2018-2030 (USD Million)
Table 8 U.S. Cell Therapy Market By Therapy Type, 2018-2030 (USD Million)
Table 9 U.S. Cell Therapy Market By Therapeutic Area, 2018-2030 (USD Million)
Table 10 Canada Cell Therapy Market By Therapy Type, 2018-2030 (USD Million)
Table 11 Canada Cell Therapy Market By Therapeutic Area, 2018-2030 (USD Million)
Table 12 Europe Cell Therapy Market By Country, 2018-2030 (USD Million)
Table 13 Europe Cell Therapy Market By Therapy Type, 2018-2030 (USD Million)
Table 14 Europe Cell Therapy Market By Therapeutic Area, 2018-2030 (USD Million)
Table 15 Germany Cell Therapy Market By Therapy Type, 2018-2030 (USD Million)
Table 16 Germany Cell Therapy Market By Therapeutic Area, 2018-2030 (USD Million)
Table 17 UK Cell Therapy Market By Therapy Type, 2018-2030 (USD Million)
Table 18 UK Cell Therapy Market By Therapeutic Area, 2018-2030 (USD Million)
Table 19 Switzerland Cell Therapy Market By Therapy Type, 2018-2030 (USD Million)
Table 20 Switzerland Cell Therapy Market By Therapeutic Area, 2018-2030 (USD Million)
Table 21 Asia-Pacific Cell Therapy Market By Country, 2018-2030 (USD Million)
Table 22 Asia-Pacific Cell Therapy Market By Therapy Type, 2018-2030 (USD Million)
Table 23 Asia-Pacific Cell Therapy Market By Therapeutic Area, 2018-2030 (USD Million)
Table 24 China Cell Therapy Market By Therapy Type, 2018-2030 (USD Million)
Table 25 China Cell Therapy Market By Therapeutic Area, 2018-2030 (USD Million)
Table 26 Japan Cell Therapy Market By Therapy Type, 2018-2030 (USD Million)
Table 27 Japan Cell Therapy Market By Therapeutic Area, 2018-2030 (USD Million)
Table 28 India Cell Therapy Market By Therapy Type, 2018-2030 (USD Million)
Table 29 India Cell Therapy Market By Therapeutic Area, 2018-2030 (USD Million)
Table 30 South Korea Cell Therapy Market By Therapy Type, 2018-2030 (USD Million)
Table 31 South Korea Cell Therapy Market By Therapeutic Area, 2018-2030 (USD Million)
Table 32 Rest Of The World Cell Therapy Market By Therapy Type, 2018-2030 (USD Million)
Table 33 Rest Of The World Cell Therapy Market By Therapeutic Area, 2018-2030 (USD Million)
List of Figures
Fig. 1 Information Procurement
Fig. 2 Primary Research Pattern
Fig. 3 Market Research Approaches
Fig. 4 Value Chain-Based Sizing & Forecasting
Fig. 5 Market Formulation & Validation
Fig. 6 Cell Therapy Market, Market Segmentation
Fig. 7 Market Driver Analysis (Current & Future Impact)
Fig. 8 Market Restraint Analysis (Current & Future Impact)
Fig. 9 PESTEL Analysis
Fig. 10 Porter’s Five Forces Analysis
Fig. 11 Global Cell Therapy Market: Therapy Type Key Takeaways
Fig. 12 Global Cell Therapy Market: Therapy Type Movement Analysis
Fig. 13 Global Cell Therapy Market For Allogeneic Therapies, 2018-2030 (USD Million)
Fig. 14 Global Cell Therapy Market For Stem Cell Therapies, 2018-2030 (USD Million)
Fig. 15 Global Cell Therapy Market For Hematopoetic Stem Cell Therapies, 2018-2030 (USD Million)
Fig. 16 Global Cell Therapy Market For Mesenchymal Stem Cell Therapies, 2018-2030 (USD Million)
Fig. 17 Global Cell Therapy Market For Non-Stem Cell Therapies, 2018-2030 (USD Million)
Fig. 18 Global Cell Therapy Market For Keratinocyte & Fibroblast-Based Therapies, 2018-2030 (USD Million)
Fig. 19 Global Cell Therapy Market For Other Non-Stem Cell Therapies, 2018-2030 (USD Million)
Fig. 20 Global Cell Therapy Market For Autologous Cell Therapies, 2018-2030 (USD Million)
Fig. 21 Global Cell Therapy Market For Autologous Stem-Cell Therapies, 2018-2030 (USD Million)
Fig. 22 Global Cell Therapy Market For BM, Blood, & Umbilical Cord-Derived Stem Cell Therapies, 2018-2030 (USD Million)
Fig. 23 Global Cell Therapy Market For Adipose Derived Cells, 2018-2030 (USD Million)
Fig. 24 Global Cell Therapy Market For Others, 2018-2030 (USD Million)
Fig. 25 Global Cell Therapy Market For Autologous Non-Stem Cell Therapies, 2018-2030 (USD Million)
Fig. 26 Global Cell Therapy Market For T-Cell Therapies, 2018-2030 (USD Million)
Fig. 27 Global Cell Therapy Market For CAR T Cell Therapy, 2018-2030 (USD Million)
Fig. 28 Global Cell Therapy Market For T Cell Receptor (TCR)-Based, 2018-2030 (USD Million)
Fig. 29 Global Cell Therapy Market For Other Autologous Non Stem-Cell Therapies, 2018-2030 (USD Million)
Fig. 30 Global Cell Therapy Market: Therapeutic Area Key Takeaways
Fig. 31 Global Cell Therapy Market: Therapeutic Area Movement Analysis
Fig. 32 Global Cell Therapy Market For Oncology, 2018-2030 (USD Million)
Fig. 33 Global Cell Therapy Market For Cardiovascular Disease (CVD), 2018-2030 (USD Million)
Fig. 34 Global Cell Therapy Market For Musculoskeletal Disorders, 2018-2030 (USD Million)
Fig. 35 Global Cell Therapy Market For Dermatology, 2018-2030 (USD Million)
Fig. 36 Global Cell Therapy Market For Others, 2018-2030 (USD Million)
Fig. 37 Regional Outlook, 2023 & 2030
Fig. 38 North America Cell Therapy Market, 2018-2030 (USD Million)
Fig. 39 U.S. Cell Therapy Market, 2018-2030 (USD Million)
Fig. 40 Canada Cell Therapy Market, 2018-2030 (USD Million)
Fig. 41 Europe Cell Therapy Market, 2018-2030 (USD Million)
Fig. 42 Germany Cell Therapy Market, 2018-2030 (USD Million)
Fig. 43 UK Cell Therapy Market, 2018-2030 (USD Million)
Fig. 44 Switzerland Cell Therapy Market, 2018-2030 (USD Million)
Fig. 45 Asia-Pacific Cell Therapy Market, 2018-2030 (USD Million)
Fig. 46 Japan Cell Therapy Market, 2018-2030 (USD Million)
Fig. 47 China Cell Therapy Market, 2018-2030 (USD Million)
Fig. 48 India Cell Therapy Market, 2018-2030 (USD Million)
Fig. 49 South Korea Cell Therapy Market, 2018-2030 (USD Million)
Fig. 50 Rest Of The World Cell Therapy Market, 2018-2030 (USD Million)

Companies Mentioned

  • Novartis AG
  • Gilead Sciences, Inc.
  • Bristol-Myers Squibb Company
  • Johnson & Johnson Services, Inc
  • JCR Pharmaceuticals Co., Ltd.
  • JW Therapeutics
  • Atara Biotherapeutics
  • MEDIPOST
  • Anterogen Co., Ltd.
  • S. BIOMEDICS

Methodology

Loading
LOADING...

Table Information